Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Nomination Committee appointed for the 2023 Annual General Meeting of Immunovia AB (Publ)

LUND, SWEDEN – According to the instructions for the Nomination Committee of Immunovia AB (Publ) that were adopted at the Annual General Meeting on April 7, 2022, the Nomination Committee shall consist of four members.    The Nomination Committee, which is to be appointed for the period until a new Nomination Committee is appointed, shall consist of four members, of which three will be appointed by the Company's three largest shareholders in terms of voting, and the fourth shall be the Chairman of the Board. In the event that the Chairman of the Board is one of the three largest

XMReality Interim report, Group overview, July – September 2022

The Annual Recurring Revenues (ARR) turned slightly in a positive direction and increased 2 percent compared to Q2 this year. Net Sales decreased by 15 percent compared with the previous period. The company also communicates its financial goals.The Quarter July – September 2022, The Group · Net sales amounted to SEK 4,482 thousand (5,286). · Costs totaled SEK -15,311 thousand (-12,777). · The operating loss before taxes was SEK -7,895 thousand (-7,022). · Cash flow was SEK -10,973 thousand (-9,294) and the equity/assets ratio at the end of the period was 52.1 (80.9) percent.

Hexagon Composites ASA: Invitation to third quarter 2022 results

20 October 2022: Hexagon Composites ASA's third quarter results 2022 will be released on 3 November 2022 at 07:00 am CET. Jon Erik Engeset, CEO and David Bandele, CFO will present the results at 08:30 am the same morning. The presentation will be held at the DEG8 building, in Dronning Eufemias gt. 8, Oslo. If you would like to attend the presentation, please pre-register by emailing ir@hexagongroup.com.The presentation will also be broadcasted live via:https://channel.royalcast.com/landingpage/hegnarmedia/20221103_11/ 

BioStock: PolarCool boosted by 5-year clinical study results

Medtech company PolarCool has developed PolarCap, a medical device that actively cools down the brain in the acute phase of an injury to decrease concussion symptoms. Results from a 5-year clinical study with the device have just been published in the Journal of Neurotrauma, and PolarCool’s CEO Erik Andersson stopped by the BioStock Studio to discuss the results.Watch the interview with PolarCool's CEO Erik Andersson at biostock.se: https://www.biostock.se/en/2022/10/polarcool-boosted-by-5-year-clinical-study-results/This is a press release from BioStock - Connecting Innovation &

Nokian Tyres: Disclosure under chapter 9, section 10 of the securities market act

Nokian Tyres plc Stock Exchange Release October 20, 2022 at 9:20 a.m. Nokian Tyres has received an announcement from BlackRock, Inc. on October 19, 2022, in accordance with the Finnish Securities Market Act Chapter 9, Section 5. According to the announcement, the indirect holding in Nokian Tyres shares owned by BlackRock, Inc. and its funds exceeded the level of 5% of the share capital in Nokian Tyres plc, as a result of share transactions concluded on October 18, 2022. The indirect shareholding of BlackRock, Inc. in Nokian Tyres has increased to 7,181,469 shares, corresponding to 5.

The ONCOS-102 phase 1b melanoma study is published in the prestigious scientific journal Clinical Cancer Research - with updated publication info

· ONCOS-102 in combination with PD-1 checkpoint inhibitor (CPI) Keytruda demonstrated strong ORR of 35% in PD-1 CPI resistant melanoma, correlating with robust and persistent immune activation · A phase 2 trial is under planning, where ONCOS-102 will be tested in a triple-combination with both PD-1 and CTLA-4 CPIs Oslo, Norway, 20 October 2022 – Targovax ASA (OSE: TRVX), a clinical-stage immuno-oncology company developing immune activators to target solid tumors, today announces that the completed ONCOS-102 phase 1b study in PD-1 CPI resistant advanced melanoma has been published in

Tarkon trusts in modern PEMA welding automation

Polish steel structure manufacturer and supplier Tarkon Sp. z.o.o. has placed an order for an automated PEMA welding solution. The order includes two PEMA Robot Welding Stations and is a significant investment for the company’s global projects in the renewable energy industry, and their wide steel structure markets. Tarkon facilities are located in Tarnobrzeg near Tarnobrzeskie Lake, on Southern East of Poland, Subcarpathian Voivodeship. Pemamek has received an order from Polish Tarkon Sp. z.o.o. The order includes two automated PEMA Robot Welding Stations to meet the company’s

WANTED: Ideas that can turn the fashion industry planet positive

The world’s largest innovation challenge to transform the fashion and textile industry is now open for applications. The Global Change Award – called the ‘Nobel Prize of Fashion’ – is part of transforming fashion and turning the entire industry planet positive. Now, we are calling innovators and entrepreneurs to apply for the GCA 2023. Five winners share a grant of 1 million euro, provided by the H&M Foundation, and get access to our one-year long GCA Impact Accelerator.The Global Change Award is one of the world’s leading challenges for early-stage innovation, and the largest of its kind

GlobalConnect commits to join the Science Based Targets initiative

Connectivity providerGlobalConnect commits to join the Science Based Targets initiative  by submitting its first-ever SBTi targets. GlobalConnect commits to set near-term company-wide emission reductions in line with climate science with the SBTi.Following a series of important sustainability milestones set during 2022 such as releasing its first joint Annual & Sustainability Report, entering the Ørsted+ATP consortium to bid for the build of the world’s first Energy Island in the North Sea and being enrolled into United Nations’ Global Compact Program –

AQ Group AB (publ), interim report January - September, 2022

Third quarter, July-September 2022 in brief   · Strong growth within electrification · Net sales increased by 31.0% to SEK 1,711 million (1,306) · Operating profit (EBIT) increased by 30.8% to SEK 123 million (94) · Profit after financial items (EBT) increased by 33.7% to SEK 121 million (91) · Profit margin before tax (EBT %) was 7.1% (6.9) · Cash flow from operating activities amounted to SEK 3 million (99) · Earnings per share after dilution increased by 31.4% to SEK 5.41 (4.12)   Nine months, January-September 2022 in brief   · Net sales increased

CapMan Growth invests in fast growing financial management software company Fennoa

CapMan Growth press release20.10.2022 at 09:00 EEST CapMan Growth invests in fast growing financial management software company Fennoa CapMan Growth invests in fast growing software company Fennoa which develops and provides cloud-based financial management software. During the last few years, the company’s revenue and profitability has increased tenfold. In addition to CapMan Growth, Finnish pension insurance company Ilmarinen also invests in the company. The company’s current CEO and founding partner Mikko Kalliovaara as well as the company’s CTO and founding partner Lasse

Conference call in connection with interim report January-September 2022

Analysts, investors and the media are invited to a conference call in connection with the publication of the interim report on Friday, 28 October at 08.45 CET. The presentation will be held in English. To attend the conference call please register using the link below. After registration you will receive dial in numbers and pin code. Please register here . The presentation material will be published on balder.se 

Alimak Group: Interim report January – September 2022

Accelerated profitable growth · Strong order intake, an increase of 10% organically · Revenue increased by 7% organically · EBITA adjusted increased by 26% · Acquisition of Tall Crane Equipment and TractelThird quarter –        Order intake increased by 25% to MSEK 1,086 (872) with an organic increase of 10% –        Strong growth in order intake in Facade Access of 57%, Construction of 20% and in Industrial of 24% –        Revenue increased by 21% to MSEK 1,095 (902) with an organic increase of 7% –        EBITA adjusted increased to MSEK 150 (119), margin 13.7% (

Interim Report for the period July – September 2022

Groundbreaking results for lecanemab in Phase 3 study in early Alzheimer's disease Events during the third quarter 2022 · Lecanemab showed positive results in the pivotal Phase 3 study, Clarity AD, in early Alzheimer's disease, and both primary and all key secondary endpoints were met with high statistical significance · New lecanemab data were presented by Eisai at the Alzheimer's Association International Conference (AAIC), including data on a subcutaneous formulation of lecanemab · The FDA accepted the Biologics License Application (BLA) and granted priority review for

Interim report, January–September 2022

Positive net leasing and good growth in income from property management· Income: SEK 6,732 M (4,437).  · Increase in income from property management of 39 per cent to SEK 3,479 M (2,503), corresponding to SEK 10.49 per share (9.14).  · Values on properties are unchanged during the quarter.  · Net income for the period: SEK 6,534 M (7,064), corresponding to SEK 19.70 (25.79) per share.  · Long-term net reinstatement value (EPRA NRV): SEK 259 per share (230), an increase of 13 per cent.  · After new construction, extensions and reconstructions totalling SEK 3,687 M (2,

Interim report Byggmax Group January 1 - September 30, 2022

Good quarter despite tough marketSummary of the third quarter 2022• Net sales amounted to SEK 2,273 M (2,400), representing a decrease of 5.3 percent.• The Group’s currency adjusted like-for-like sales decreased by 11.4 percent.• The gross margin was 34.4 percent (34.8).• EBITA amounted to SEK 288 M (406), with an EBITA margin of 12.7 percent (16.9).• EBIT amounted to SEK 274 M (395), with an EBIT margin of 12.0 percent (16.4).• Net profi t for the period amounted to SEK 214 M (306).• Earnings per share totaled SEK 3.65 (5.02).• Cash flow from operating activities amounted

Nexam Chemical Holding AB (publ) Interim Report 1 January – 30 September 2022

Growth with increased margins during the quarterThird quarter at a glance Significant events: · Sales increased by 13% in the quarter and margin from 36% to 39%. · Performance Masterbatch increased by 9% and Performance Chemical by 17%, compared with the corresponding quarter in 2021. · Takes the first major order in South Korea within Reactive Recycling to a value of SEK 1m. · Christer Svanberg hired as new CTO, starts in November. · Started the installation of new machine line in Lomma. Financials: · Net sales during quarter amounted to SEK 56,719,000 (50,229,

News conference on Kojamo’s Interim Report for January–September 2022 on 3 November 2022

Kojamo plc Press Release, 20 October 2022 at 9:00 a.m. EESTNews conference on Kojamo’s Interim Report for January–September 2022 on 3 November 2022 Kojamo plc’s Interim Report for January–September 2022 will be published on Thursday, 3 November 2022 at approximately 8:00 a.m. EET. News conference and webcast Kojamo will hold a news conference for institutional investors, analysts and media on 3 November 2022 at 10:00 a.m. EET at its headquarters at Mannerheimintie 168A, Helsinki, Finland. The event will be hosted by Kojamo’s CEO Jani Nieminen and CFO Erik Hjelt, and it will be held

Interim Report January–September 2022

Third quarter · Order intake amounted to SEK 1,609 (1,242) million, an increase of 30 percent · Net sales increased 23 percent to SEK 1,214 (986) million. Based on constant exchange rates, net sales increased10 percent · EBIT amounted to SEK 203 (106) million and the EBIT margin was 17 (11) percent  · Earnings per share were SEK 1.56 (0.82) January–September · Order intake amounted to SEK 4,253 (3,272) million, an increase of 30 percent · Net sales increased 8 percent to SEK 3,622 (3,341) million. Based on constant exchange rates, net sales decreased1 percent ·

Metso Outotec and Boliden sign a 5-year Life Cycle Services contract including recycling of worn liners

Metso Outotec Corporation’s press release on October 20, 2022, at 09:00 a.m. EESTMetso Outotec and Boliden have signed a Life Cycle Services (LCS) contract for Boliden’s Kevitsa mine in the Sodankylä region in Finland. The 3+2-year agreement covers the supply and optimization services of the Megaliner™ liners for four mills with advanced discharge systems, supported by shutdown planning and execution services of the mill linings. The agreement also covers a novel Planet Positive  mill lining recycling service

Hansa Biopharma Interim report January-September 2022

· Total Revenue of SEK 67m in the third quarter 2022 · Positive reimbursement decisions received in Poland and Scotland · $70 million raised in non-dilutive financing · Imlifidase included in ESOT guidelines published in Transplant InternationalLund, Sweden October 20, 2022, Hansa Biopharma, the pioneer in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced its business update and interim report for January to September 2022. Highlights for the third quarter 2022 · Total Q3 revenue of SEK 67m including SEK 23m in product sales and SEK 44m

Stable Q3 sales and very strong first nine months of 2022

STOCKHOLM – Oct 20, 2022- ContextVision, a medical technology software company specializing in image processing and image analysis, today reports its third quarter results.Our Q3 revenues came in at 26.9 MSEK compared to 26.0 in last year, down 3 % from last year. Currencies played a role and had a positive impact of 7MSEK.  Our comparison quarter in 2021 was exceptionally strong due to one off bookings that was done during that quarter. Our 9 months revenue came in at 86.6 MSEK compared to 70.7 MSEK last year, resulting in an overall growth of +23% for the first nine months of 2022. EBITDA

Hemnet Group Interim report Q3 2022

Summary for the period July-September 2022 · Net sales increased by 22.0 percent to SEK 238.9m (195.8) · Adjusted EBITDA increased 25.6 percent to SEK 128.5m (102.3) · Operating profit increased 34.1 percent to SEK 110.9m (82.7) · ARPL, average revenue per published listing, increased 28.8 percent to SEK 3,404 (2,642)  Summary for the period January-September 2022 · Net sales increased by 24.9 percent to SEK 688.2m (550.8) · Adjusted EBITDA increased 32.9 percent to SEK 359.3m (270.4) · Operating profit increased 92.3 percent to SEK 306.2m (159.2) · ARPL,

There are no items matching the current filter
There are no more items matching the current filter
Back to top